Last reviewed · How we verify

NCT05224557

Analysis of Cardiac Biomarker Racial Discrepancies

ENROLLING BY INVITATION Last updated 20 March 2026
What this trial tests

trial testing No intervention in Heart Failure in 400 participants. Enrolling by invitation.

Timeline
15 September 2021
Primary endpoint
15 August 2027
15 September 2028

Quick facts

Lead sponsorMethodist Health System
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment400
Start date15 September 2021
Primary completion15 August 2027
Estimated completion15 September 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Methodist Health System — full company profile →

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal is to review cardiac biomarkers present on admission between African American patients with new onset Heart Failure compared to a comparable cohort of Caucasian patients to establish whether there is a clinically significant difference between the two groups regarding cardiac biomarker levels and initial Heart Failure severity. Hypothesis: Cardiac biomarker levels in African American patients with new onset Heart Failure with Reduced Ejection Fraction will be significantly lower than a Caucasian cohort with new onset Heart Failure with Reduced Ejection Fraction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Methodist Health System trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05224557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing